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Abstract
Paget’s disease of bone (PDB) is a chronic bone disorder and although genetic factors
appear to play an important role in its pathogenesis, to date PDB causing mutations were
identified only in the Sequestosome 1 (SQSTM1) gene at the PDB3 locus. PDB6 locus, also
previously linked to PDB, contains several candidate genes for metabolic bone diseases.
We focused our analysis in the most significantly associated variant with PDB, within the
Optineurin (OPTN) gene, i.e. the common variant rs1561570. Although it was previously
shown to be strongly associated with PDB in several populations, its contribution to PDB
pathogenesis remains unclear. In this study we have shown that rs1561570 may contribute
to PDB since its T allele results in the loss of a methylation site in patients’ DNA, leading to
higher levels of OPTN gene expression and a corresponding increase in protein levels in
patients’ osteoclasts. This increase in OPTN expression leads to higher levels of NF-κB
translocation into the nucleus and increasing expression of its target genes, which may con-
tribute to the overactivity of osteoclasts observed in PDB. We also reported a tendency for a
more severe clinical phenotype in the presence of a haplotype containing the rs1561570 T
allele, which appear to be re-enforced with the presence of the SQSTM1/P392L mutation. In
conclusion, our work provides novel insight towards understanding the functional effects of
this variant, located in OPTN intron 7, and its implication in the contribution to PDB
pathogenesis.
Introduction
Paget’s disease of bone (PDB) is a metabolic bone disorder that affects between 1% and 3% of
Caucasians over the age of 55 [1–3]. This disease is characterized by focal abnormal bone
remodelling, with increased bone resorption and accelerated, excessive and disorganized new
bone formation. The pathophysiology of PDB is currently an area of intensive investigation
and both genetic and non-genetic factors have been implicated. Fifteen to 40 percent (15–
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40%) of affected patients have a first-degree relative with PDB and numerous studies have
described large families with PDB exhibiting an autosomal dominant mode of inheritance [3–
5]. Linkage studies in these families have identified a number of susceptibility loci on chromo-
somes 6p21 (PDB1) [6], 18q21.1–22 (PDB2) [7], 5q35 (PDB3), 5q31 (PDB4) [5], 2q36 (PDB5)
[8], 10p13 (PDB6) [9] and 18q23 (PDB7) [8]. These regions contain many genes that could be
plausible candidates based on their known functions. A genome-wide scan in British families
with PDB has shown a linkage to the 10p13 (PDB6) locus [9,10] and reanalysis of data from
this genome-wide scan confirmed this genetic association [11], namely to the common variant
rs1561570 (hg19, chr10:g.13155726 T>C) in the Optineurin (OPTN) gene. Our group has also
replicated the strong, statistically significant, genetic association of rs1561570 (p-value =
5.65×10−7) with PDB in the French-Canadian population [12]. OPTN gene has been previously
linked to glaucoma [13] and neurodegenerative diseases, like Alzheimer’s, Parkinson’s or
amyotrophic lateral sclerosis [14]. It was also found to be important for several cellular events
such as membrane trafficking and maintenance of the Golgi complex, autophagy and protein
turnover through the ubiquitin-proteasome pathway [15–18]. OPTN has been characterized as
an autophagy adaptor protein, which regulates selective autophagy of ubiquitin-coated cyto-
solic proteins, organelles and parasites such as Salmonella enterica. This function depends on
the phosphorylation of its LC3-interacting motif by TANK-binding kinase 1 (TBK1) [16,18–
20]. OPTN can also mediate protein aggregate removal through a ubiquitin-independent
mechanism [21] and, in addition, it seems to be part of the TNFα pathway, contributing to
mediate the availability of NF-κB in the cell [22,23]. A possible role for OPTN in bone was
recently described by Obaid et al. (2015) who have shown that mice harbouring a loss-of-func-
tion mutation in Optn presented an increase in osteoclast activity and in bone turnover, thus
indicating that this protein could be acting as a negative regulator of osteoclast differentiation,
possibly by inhibiting NF-κB activation [24]. Despite these findings, this animal model did not
develop a PDB-like phenotype. Previously, in a different model and in contrast with those
results, OPTN was described as being involved in the activation of NF-κB pathway [25]. In-
deed, Journo and colleagues (2009) have observed that in human cells, infected with the
human T lymphotropic virus type 1, OPTN increased the ubiquitination of Tax1 as well as
Tax1-dependent NF-κB signalling, thus promoting NF-κB activation, a result that is in agree-
ment with other studies [26–28]. These discrepancies suggest that the pathologies linked to
OPTN cannot be associated exclusively to its loss of function, but more likely to its aberrant
expression, resulting from either mutant or gain of OPTN function affecting different path-
ways in distinct biological contexts, and which are not yet fully understood. Therefore, addi-
tional work is required to understand the complexity of the events associated to OPTN
function, namely using ex-vivo tools such as PDB patients’ samples. In the present work
the effect in osteoclastogenesis of the most significantly PDB-associated OPTN variant
(rs1561570) was assessed using patients’ monocytes as study model. These cells are precursors
of osteoclasts and can be induced to fuse in order to originate mature osteoclast cells in vitro.
The results obtained are expected to contribute to further elucidate the role of OPTN in the
pathophysiology of a complex chronic bone disease such as PDB.
Materials and methods
Study participants
This study was approved by the CHU de Que´bec-Universite´ Laval Ethics Committee and all
participants have signed a consent form before inclusion in the study. We investigated patients
with familial form of PDB (one patient per family, to avoid the biais of relatedness in our
genetic association analysis), unrelated PDB patients and healthy controls, all from the
Rs1561570 effect in Paget’s disease of bone
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French-Canadian population. The intra familial cosegregation of the T allele among affected
relatives within familial forms was not performed. All patients and healthy donors studied
here were non-carrier of the P392L mutation within the SQSTM1 gene (PDB3 locus). For the
PDB osteoclastic phenotype characterization and to assess the potential synergistic effect of
rs1561570 with SQSTM1/P392Lmutation in osteoclastogenesis, we studied a patient heterozy-
gous for rs1561570 (CT genotype) and also carrier of the P392L mutation in SQSTM1. Pheno-
type assessment, DNA and RNA extraction methods are detailed in the S1 File.
Bioinformatic analysis
To analyse if rs1561570 was affecting the methylation status at that particular location we used
the MethPrimer (http://www.urogene.org/methprimer/), an in silico tool used to predict CpG
island by examining the CG dinucleotides and to design specific primers to analyse those CpG
islands (S1 Table).
Methylation analysis by bisulfite conversion and sanger sequencing
Sodium bisulfite treatment was performed on 1.5 μg of genomic DNA sample using the Epi-
Mark1 Bisulfite Conversion Kit [29] (New England Biolabs Inc., Canada) following the man-
ufacturers’ standard protocol. Further details are provided in the S1 File.
Cell culture conditions
The U937 (Human monocytes/lymphoma) and U2OS (Human bone osteosarcoma) cell lines
were grown in Dulbecco’s modified eagle medium (DMEM), supplemented with 10% fetal
bovine serum (FBS), 2mM L-glutamine and 1% penicillin/streptomycin (P/S). The T47D
(Human breast carcinoma) cell line was grown in RPMI-1640 medium supplemented with
10% FBS, and 1% P/S. The MG63 (Human bone osteosarcoma) cell line was grown in αMEM
supplemented with 10% FBS, and 1% P/S. All cell lines were incubated at 37˚C in a humidified
atmosphere containing 5% CO2. The medium, FBS, antibiotics and glutamine were obtained
from Invitrogen, Portugal. Cell lines were obtained from American Type Culture Collection
(ATCC).
Demethylating treatment and immunofluorescence
The localization of NF-κB after treatment with 5-Azacitidine (5-Aza, Sigma-Aldrich, Portugal)
for 72h in T47D and U937 cell lines was assessed by immunofluorescence. NF-κB localization
was also assessed by immunofluorescence in osteoclasts derived from Peripheral Blood Mono-
nuclear Cells (PBMCs) from healthy donors and PDB patients with all studied genotypes. The
immunofluorescence protocol is described in the S1 File.
Preparation of human in vitro-differentiated mature osteoclasts
Human mature osteoclasts were differentiated in vitro using mononuclear cells from blood of
healthy controls and PDB patients. PBMCs were obtained by density gradient centrifugation
using Ficoll-Hypaque. The cells were resuspended (3x106 cells/mL) in OPTI-MEM containing
10% FBS. The cell suspension was added to 6-well plates (9x106 cells/well) and to Lab-Tek 8
well-slides (3-6x105 cells/well). After 24h, the cells were washed thoroughly and lymphocyte-
free adherent cells were incubated for three weeks with M-CSF (25 ng/ml, Life technologies,
Canada) and RANKL (30 ng/ml, Fitzgerald, Canada).
Rs1561570 effect in Paget’s disease of bone
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Osteoclast morphology assessment, TRAP assay and in vitro assessment of
bone resorption
Mature osteoclast formation was evaluated by quantification of TRAP-positive multinuclear
cells using an acid phosphatase kit (Sigma-Aldrich, Canada), according to the protocols pro-
vided by the manufacturer. The bone resorption activity of osteoclasts was tested in vitro,
using a previously validated model [30]. The details of the TRAP assay and the in vitro assess-
ment of bone resorption are provided in the S1 File.
Quantitative real-time PCR
In order to test if the most strongly PDB associated OPTN variant had an impact on its gene
expression, we performed qPCR as previously described [12]. The details of this analysis are
provided in the S1 File.
Western blot analysis
Osteoclasts derived from patients and controls PBMCs were washed once in PBS and lysed
using Trizol. The protein concentrations were determined using the Bradford reagent (Bio-
Rad, Canada). Proteins were separated by 8% SDS-polyacrylamide gels and transferred onto
PVDF membranes (Life technologies, Canada). After transfer, the membranes were blocked in
0.1% TBS/Tween 20 containing 5% nonfat dried milk at room temperature for 1 h. The mem-
branes were then incubated overnight at 4˚C with anti-OPTN (1:500, #100000 Cayman, Can-
ada), anti-LC3B (1:1000, #2775 Cell Signaling, Canada) or anti-αTubulin (1:2000, #2144 Cell
Signaling, Canada) in 0.1% TBS/Tween 20, followed by extensive washing using 0.1% TBS/
Tween 20 and an incubation with HRP-conjugated secondary antibody (1: 2000, Cell signal-
ing, Canada) in 0.1% TBS/Tween 20 during 1h, at room temperature. After extensive washing
with 0.1% TBS/Tween 20, specific proteins were detected using a chemiluminescence kit (GE
Healthcare, Canada). The densitometric analysis was performed using ImageJ software.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5 (GraphPad, La Jolla, CA). Compari-
sons between two groups were made using a two-tailed Student’s t-test. For comparisons
between multiple groups, one-way ANOVA followed by Tukey’s post-hoc test was used. Dif-
ferences were considered statistically significant when p<0.05.
Results
Rs1561570 increases in vitro osteoclast differentiation and bone resorption
activity
To better assess the effect of rs1561570 on osteoclasts formation, we performed a TRAP assay
in osteoclasts derived from the PBMCs of patients carrying the rs1561570 C or the T allele. The
presence of a haplotype with at least one T allele for rs1561570 increased significantly osteo-
clast formation, attested by the mean number of multinucleated cells yielded from PBMCs cul-
tures, when compared to healthy controls (Controls CC 10%, Patients CC 50%, Patients CT/TT
80%, p-value = 0.006) (Fig 1A and 1C). The osteoclasts generated displayed a higher mean
number of nuclei than the osteoclasts from healthy controls (Controls CC mean = 3, Patients
CC mean = 5, Patients CT/TTmean = 10, p-value = 0.002) (Fig 1B and 1C).
Accordingly, bone resorption was also significantly increased in osteoclast cultures gener-
ated from patients with a haplotype carrying at least one T allele for rs1561570, resulting in
Rs1561570 effect in Paget’s disease of bone
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3-fold increase in the total bone resorption area when compared to cultures prepared from
healthy controls (p-value< 0.001) (Fig 2A and 2B) and 1.4-fold increase when compared to
cell cultures prepared from PDB patients carrying two C alleles (p-value = 0.05). We also ana-
lysed the bone resorption area from osteoclast cultures of one patient carrying a haplotype
with one T allele (CT) in combination with the SQSTM1/P392Lmutation. Interestingly, there
was an increase of the bone resorption area in the patient with one T allele, suggesting that
there might be a synergistic effect of OPTN and SQSTM1 genetic variants in PDB (Fig 2B).
Rs1561570 does not affect autophagy
OPTN has been suggested to be an autophagy adaptor and since impairment in autophagy was
reported in PDB, we assessed the autophagy process in patients with a haplotype carrying at
least one rs1561570 T allele. By immunofluorescence and western blot analysis we found that
Fig 1. Effect of rs1561570 in osteoclast differentiation. (A) The osteoclast differentiation rate (displayed as a ratio between multinucleated
osteoclasts (Multi OCL) and TRAP positive (+) cells) was higher in patients with PDB carrying at least one T allele (Patients CT/TTvs Controls CC
p-value< 0.01; Patients CT/TTvs Patients CC p-value< 0.05). (B) Osteoclasts from patients carrying at least one T allele contained significantly
more nuclei than osteoclasts from healthy controls (Patients CT/TTvs Controls CC p-value< 0.001; Patients CT/TTvs Patients CC p-value< 0.01).
(C) The images are representative of the distribution of nuclei number observed in osteoclasts generated from PBMCs derived from healthy controls
and PDB patients that were stained for TRAP and counterstained with haematoxylin. (ANOVA,  represents a p-value< 0.05,  represents a p-
value< 0.01,  represents a p-value< 0.001,  represents a p-value< 0.0001; non-mutated controls with CC genotype (n = 3), non-mutated
patients with CC genotype (n = 5) and patients carrying at least one T allele (n = 3).
https://doi.org/10.1371/journal.pone.0197543.g001
Rs1561570 effect in Paget’s disease of bone
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LC3BII expression was impaired, however that effect did not seem to be dependent of the pres-
ence of a haplotype with the T allele (S1A and S1B Fig), suggesting that the autophagy
impairment may be independent from the rs1561570 genotype.
Rs1561570 causes a change in methylation and increases OPTN expression
Since our previous study has shown a strong association between rs1561570 (located in OPTN
intron 7) and PDB [12], we determined the functional effect of rs1561570 in that disease by
employing the splice site prediction algorithm, and showed that the allele harbouring a C was
likely to create a potential new acceptor site for splicing and disrupt a potential branch point
(consensus value for mutant sequence = 69.7%) (S2 Table). To validate this finding, we per-
formed RT-PCR and qPCR using cDNA samples from patients and healthy controls with the
three genotypes. Retention of intronic sequences was not observed in the genotypes analysed
(results not shown).
Fig 2. Effect of rs1561570 in bone resorption. (A) Representative images of in vitro bone resorption assays (left) with (B) quantification of
the results (right) by using ImageJ. The bone resorption area was higher in patients with PDB carrying at least one T allele (Patients CT/TTvs
Controls CC p-value< 0.001; Patients CT/TTvs Patients CC p-value< 0.01). This result was even more evident in one PDB patient carrying
one T allele (CT genotype) plus the SQSTM1/P392Lmutation (p-value< 0.001). At least three different wells per patient were analysed.
(ANOVA,  represents a p-value< 0.05,  represents a p-value< 0.01,  represents a p-value< 0.001,  represents a p-value< 0.0001;
non-mutated controls with CC genotype (n = 3), non-mutated patients with CC genotype (n = 5) and patients carrying at least one T allele
(n = 3)).
https://doi.org/10.1371/journal.pone.0197543.g002
Rs1561570 effect in Paget’s disease of bone
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We then studied the predicted impact of rs1561570 in the OPTN methylation status using
the Methprimer tool. We found that the allele C was predicted to form a CpG dinucleotide,
creating a methylation site, which was not predicted in the presence of the T allele (Fig 3A).
After bisulfite treatment, we confirmed that all samples with at least one C allele in their
rs1561570 genotype were in fact methylated (Fig 3B). To correlate the methylation site created
by the C allele with the OPTN transcriptional levels, we performed qPCR (Fig 3C) and western
blot (Fig 3D) analysis using lymphocytes from patients with the three genotypes. Samples car-
rying a haplotype with the T allele (CT or TT) showed levels of OPTN gene and protein expres-
sion higher than samples carrying the CC genotype. This result suggested that the methylated
C allele is associated with a decrease in OPTN gene expression levels. The protein expression
levels were also measured by western blot analysis in PBMC-derived osteoclasts and the results
were in accordance with those obtained by qPCR and western blot analysis in lymphocytes
(Fig 3E).
Fig 3. Rs1561570 effect in methylation and OPTN expression. (A) In silico prediction using Methprimer tool showing a methylation site
only in the presence of the allele C (not the allele T). (B) Sequencing results showing that rs1561570 C allele after bisulfite treatment remains
a C (arrow head), while other C nucleotides that are not methylated change to T (asterisk). (C) Analysis of OPTN gene expression in
lymphocytes from several healthy controls (CC genotype n = 10, CT/TT genotypes n = 6) and PDB patients (CC genotype n = 10, CT/TT
genotypes n = 22) with the three genotypes. The levels of OPTN gene expression were measured by qPCR normalized to PPIB gene
expression levels. Values are the mean of two replicates in each experiment and the experiment was repeated at least three independent
times. (D) Quantification and (E) representative blots of OPTN protein expression in lymphocytes from non-mutated controls with CC
genotype (n = 5), and patients carrying at least one T allele (n = 19). (F) Quantification and (G) representative blots of OPTN protein
expression in osteoclasts from non-mutated controls with CC genotype (n = 3), non-mutated patients with CC genotype (n = 5) and patients
carrying at least one T allele (n = 3). The levels of OPTN protein expression were measured by western blot analysis and related to levels of α-
Tubulin (t-test and ANOVA,  represents a p-value< 0.05). The figures are representative of all the western blot analyses performed (n = 3).
https://doi.org/10.1371/journal.pone.0197543.g003
Rs1561570 effect in Paget’s disease of bone
PLOS ONE | https://doi.org/10.1371/journal.pone.0197543 May 21, 2018 7 / 16
Rs1561570 increases NF-κB translocation into the nucleus
To determine the role of rs1561570 on the osteoclastic phenotype, and since there are previous
publications describing OPTN as an important protein in NF-κB pathway [25], we analysed
the NF-κB cellular localization by immunofluorescence in PBMC-derived osteoclasts from
PDB patients carrying different genotypes of rs1561570 and from healthy controls. Our results
showed NF-κB translocation to the nucleus (showed as a ratio between co-localization of NF-
κB and DAPI) is increased in patients with genotype CT and TT (Fig 4A). To confirm that the
Fig 4. Effect of rs1561570 in NF-κB localization and in the expression of NF-κB target genes in osteoclasts of patients with PDB. (A) NF-κB
localization in osteoclasts derived from healthy controls and patients PBCMs showing an increase of the translocation of NF-κB into the nucleus, in
patients with genotype CT and TT. This was also confirmed by co-localization ratio between NF-κB and DAPI–the nuclear staining. Five different
fields of view were analysed per sample and at least three different samples were analysed per patient. Co-localization coefficient was calculated by
Volocity software as the ratio of NF-κB staining related to DAPI. (B) Analysis of NFATc1, IL6, TRAP and ELK1 gene expression in several healthy
controls (n = 16) and PDB patients (CC n = 10, CT/TTn = 22) with all genotypes. The levels of NFATc1 , IL6, TRAP and ELK1 expression were
measured by qPCR related to levels of PPIB. Values are the mean of at least three independent replicates. (t-test,  represents a p-value< 0.05, 
represents a p-value< 0.01).
https://doi.org/10.1371/journal.pone.0197543.g004
Rs1561570 effect in Paget’s disease of bone
PLOS ONE | https://doi.org/10.1371/journal.pone.0197543 May 21, 2018 8 / 16
presence of NF-κB in the nucleus was affecting the expression of its target genes, we measured
the expression of NF-κB, IL-6, ELK1, TRAP and NFATc1 expression. Our results showed an
increased expression of NF-κB target genes related with osteoclastogenesis, such as IL-6, ELK1,
TRAP and NFATc1 (Fig 4B)–thus providing additional evidence that an increase of OPTN
expression observed in the presence of the T allele in the OPTN methylation status leads to an
increase of NF-κB translocation into the nucleus and an increase of its target genes expression.
As a proof of concept, we also analysed the NF-κB cellular localization by immunofluores-
cence in two different cell lines which carry the rs1561570 C allele–T47D (CT genotype) and
U937 (CC genotype)–following a treatment with a demethylating agent, 5-Azacitidine. We
were able to confirm that, before the demethylating treatment, NF-κB was localized in the
cytoplasm and in the nucleus. However, after OPTN demethylation, NF-κB localization was
almost exclusively located in the nucleus (Fig 5A and 5B). To confirm the effect of the demeth-
ylating agent we measured OPTN expression and to confirm that the presence of NF-κB in the
nucleus was also affecting the expression of its target genes (as in patients carrying the T allele),
we measured the expression of NF-κB, IL-6, ELK1, TRAP and NFATc1. Our results showed
Fig 5. In vitro effect of OPTN demethylation in NF-κB localization and expression of NF-κB target genes. (A) NF-κB localization in U937 cells (CC genotype). (B)
NF-κB localization in T47D cells (CT genotype), following 5-Azacitidine (5-Aza) treatment. After OPTN demethylation, NF-κB was translocated exclusively to the
nucleus. (C) Analysis of NF-κB target genes expression. The levels of OPTN, NF-κB and NF-κB target genes (IL-6, ELK1,NFATc1) expression were measured by qPCR
related to levels of GAPDH gene. Values are the mean of at least three independent replicates. (t-test,  represents a p-value< 0.05,  represents a p-value< 0.01 
represents a p-value< 0.001,  represents a p-value< 0.0001).
https://doi.org/10.1371/journal.pone.0197543.g005
Rs1561570 effect in Paget’s disease of bone
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that there was an increase both in OPTN expression, which was expected after the demethyla-
tion treatment, and in the expression of the NF-κB target genes analysed. NF-κB levels were
maintained as expected (Fig 5C).
In addition we performed the same procedure using two osteosarcoma cell lines–U2OS
(CC genotype) and MG63 (TT genotype) and the results showed that the demethylating agent
increased OPTN and NF-κB target genes in U2OS while NF-κB expression was maintained
(S2A Fig), suggesting that a change in the methylation status due to the effect of the demethyl-
ating agent had an effect in OPTN and in NF-κB target genes expression. In contrast, in the
MG63 cell line this treatment did not have any effect in the expression of OPTN or NF-κB tar-
get genes (S2B Fig), suggesting that the effect in OPTN expression might be specific for the
cells carrying one C allele, thus supporting our hypothesis.
Rs1561570 may have an effect on PDB severity in the presence of SQSTM1
mutations
By comparing the clinical phenotype of patients with PDB carriers of the CC genotype of
OPTN rs1561570 with patients carrying one or two T alleles, we observed a tendency, although
not significant, for an: i) increase of total serum ALP (sALP) levels, ii) increase of mean num-
ber of affected bones, and iii) increase of disease extension measured by Renier’s index–related
with the number of T alleles in the genotype (S3 Table). These results suggest that rs1561570
could have a dose effect depending on the number of T alleles present in the genotype. In fact,
in the presence of the P392L/SQSTM1mutation and rs1561570 T allele our results showed an
increased tendency for i) higher levels of total sALP, ii) higher risk for polyostotic involvement,
iii) higher number of affected bones and iv) an increase in the disease extension/Renier’s index
(S4 Table) with the increase in the number of T alleles. Altogether, these results may suggest a
modifier effect of OPTN common variant in the presence of SQSTM1/P392Lmutation in
patients with PDB, which could lead to an increase in the disease activity and extent, and there-
fore should be replicated in independent cohorts with higher number of participants.
Discussion
In the present study, we investigated the functional role of the most significantly PDB associ-
ated genetic variant of OPTN- rs1561570 (C>T). Previously, we reported that the C allele was
more frequent in controls in the French-Canadian population (C allele frequency = 52%, T
allele frequency = 48%) while the T allele was more frequent in PDB patients (C allele fre-
quency = 36%, T allele frequency = 64%) [12]. Using in silico tools, we found that the
rs1561570 T allele was predicted to cause the loss of a methylation site. With bisulfite treat-
ment, we confirmed that the C allele in that position was always methylated. Furthermore,
both qPCR and western blot analysis correlated the presence of the C allele with a decrease of
OPTN expression levels. The existence of a correlation between the hypermethylation status of
a given gene, resulting in a decrease in gene transcription levels affecting a related disease, has
been previously reported in the literature [31–33]. Our immunofluorescence analysis also
allowed us to confirm that an increase in OPTN levels (due to the demethylation treatment in
cells and the presence of at least one T allele in PDB patients—dominant genetic effect) is
related to an increase in NF-κB translocation into the nucleus, confirming that a decrease in
OPTN methylation (as seen in PDB patients with rs1561570 T allele) increases the transloca-
tion of NF-κB into the nucleus, and that is related to an increased expression of NF-κB target
genes related with osteoclastogenesis, such as NFATc1 –a master transcription factor of osteo-
clast differentiation [34], IL6—an important cytokine for osteoclastogenesis [35] and ELK1—a
relevant transcription factor in mature osteoclasts [36]. We also showed that the autophagy
Rs1561570 effect in Paget’s disease of bone
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process is impaired in PDB patients and that it is not dependent on the rs1561570 genetic sta-
tus. Therefore, we can hypothesize that in healthy individuals, the autophagy process works
normally both in the presence of the C allele (when the OPTN expression is controlled at basal
levels), and in the presence of the T allele (when the OPTN expression is potentiated due to the
loss of a methylation site). In the latter, the efficient autophagy process signals the excessive
OPTN for degradation by ubiquitination and recycling of the protein, and thus OPTN expres-
sion is reduced to a basal level. In both situations, this will result in normal levels of NF-κB in
the nucleus and physiological osteoclastogenesis rate. In PDB patients, where the autophagy
process is impaired, in the presence of the rs1561570 C allele, the PDB phenotype might be
explained by the presence of other factors, such as other genetic variants or environmental
triggers that will lead to an increase in osteoclastogenesis. The effect of rs1561570 T allele in
PDB patients may therefore be explained by the increase in OPTN expression associated with
a decrease in its degradation due to the autophagy defect present in these patients. Conse-
quently, there is an accumulation of OPTN that promotes NF-κB translocation to the nucleus
at a much higher rate than normal, thus also promoting osteoclastogenesis and that in addition
to the existence of other genetic variants or environmental triggers potentiate the clinical phe-
notype of PDB in these patients.
Journo and its co-workers had already described the translocation of NF-κB into the
nucleus due to an increase in OPTN expression [25], but upon a virus infection. OPTN is part
of a complex, which also includes TAX1 and TAX1BP1, that can activate the IKK complex by
ubiquitination, thus leading to the degradation of the NF-κB inhibitor and subsequent release
of NF-κB into the nucleus. In the present work, the change in OPTN expression levels caused
by one single change in nucleotide may be explained by the alteration of the already reported
binding of an enhancer—JUND, a member of the AP1 family that is present in osteoclasts
[37–39]—in the genomic region containing the T allele, which is lost in the presence of the C
allele, as confirmed by the ENCODE project. The ENCODE project shows regions of tran-
scription factor binding, derived from a large collection of ChIP-seq experiments, together
with DNA binding motifs identified within these regions by the ENCODE Factor book reposi-
tory. Indeed, due to the resulting change in DNA conformation in the presence of the T allele,
the loss of a JUND binding site around the rs1561570 region of these patients will result in an
alteration in OPTN expression levels, promoting an increase in osteoclastogenesis and the
development of PDB. Our results are in contrast with data from Obaid et al. (2015) who, based
in the description by Zeller and Westra’s groups (who have shown that rs1561570 T allele was
related to lower levels of OPTN expression [40,41]), analysed the effect of a lack of OPTN in
the differentiation of osteoclasts using a mouse knock out for OPTN. Those authors concluded
that depletion of OPTN in that model increased the differentiation of osteoclasts (p-value =
0.002), suggesting that OPTN might be a negative regulator of osteoclast differentiation [24].
However, and, unlike in humans, these mice did not develop a PDB-like phenotype [24],[17].
Interestingly, in the same study, authors also refer that OPTN expression was significantly
increased during days 2 to 5 of in vitro osteoclast differentiation using primary bone-marrow-
derived macrophages, in which they knocked down OPTN by using a small hairpin RNA. In
addition, it was found in another set of in vivo works, using either knock-in mice expressing a
point mutation in OPTN and abolishing its polyubiquitin binding capacity [42], or mice lack-
ing either the entire C-terminal ubiquitin-binding [43] or the N-terminal TANK-binding
kinase 1 (TBK1)-binding domain [44], that mice had retained normal NF-κB responses. These
results argued against the fact that a decrease per se in OPTN or in OPTN function could pro-
mote osteoclastogenesis by affecting NF-κB signalling pathways.
As referred in a recent review, OPTN was thought to be important for NF-κB signalling
because of its strong homology to the NF-κB essential modulator, NEMO—the core element
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of the inhibitor of NF-κB kinase (IKK) complex -, that is essential for NF-κB activation [18].
Altogether, the lack of a PDB-like phenotype developed in those studies is not in favour of a
lack of OPTN expression being the causing factor. As suggested in the same review, it is more
likely that the PDB phenotype is the result of an aberrant expression of OPTN, including a pos-
sible gain of function [18] which is in agreement with our results. Our study is unique since it
analyses, using in vitro and ex vivo techniques, the single effect of rs1561570 in OPTN gene and
protein expression in several samples of patients with PDB non carriers of a SQSTM1/P392L
mutation, and in different cell types (lymphocytes and osteoclasts derived from patients
PBMCs), thus providing, at several levels, clear evidences supporting our hypothesis. Our find-
ing that, in one patient carrying the SQSTM1/P392Lmutation, there was a tendency for a
more severe clinical phenotype in the presence of a haplotype with the rs1561570 T allele and
that osteoclasts from that patient had a higher in vitro bone resorption rate, suggests that there
might be a synergistic effect but this should be further investigated with additional patients.
Altogether, the gathered evidence obtained from gene to protein analysis, from in vitro to
patient samples, from genetic to morphological cellular features, show that OPTN appears to
be important for NF-κB translocation into the nucleus, activation of its target genes and conse-
quent increase in osteoclastogenesis, providing relevant information towards a better under-
standing on how genetic variants in OPTN can contribute to PDB by acting as modifiers and
complementing previous data on the potential functional role of variants in OPTN and how
they may contribute to affect the physiological regulatory mechanisms of this gene [45].
Conclusions
In conclusion, we have shown that rs1561570 is responsible for a change in the methylation
status of OPTN in patients with PDB and that it has an impact in its expression levels, which
may contribute to PDB pathogenesis by affecting NF-κB translocation to the nucleus. Accord-
ingly, to this date, OPTN remains the most likely gene within PDB6 locus to contribute to PDB
pathophysiology, possibly in combination with other genetic/environmental factors yet
unknown.
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